EN SV HOME ABOUT AT A GLANCE At a glance Focus on rare diseases Business strategy Partnership Board of directors Executive committee Corporate Governance Annual General Meetings Nomination Committee Committees Remuneration Auditors Articles of association History At a glance At Sobi, we are transforming life for people with rare diseases. As an international biopharmaceutical company, we provide access to innovative treatments in the areas of haematology, immunology and specialty care. Two therapeutic areas – Haematology and Immunology – and a portfolio of products within Specialty Care Our extended half-life factor replacement treatments are the most prescribed treatments for haemophilia A and B respectively in several markets A strong portfolio of on-market products, and an extensive portfolio of pre-market assets An international biopharmaceutical company covering the entire value chain We put our focus where we can have the greatest impact, in late-stage research and development, and in patient access and commercialisation Revenue of SEK 15.3 bn for the full year 2020 Global Head Office in Stockholm, with offices in more than 30 countries, delivering treatments to patients in more than 70 countries Approximately 1,500 employees globally The Sobi share (STO:SOBI) is listed in the Large Cap segment at Nasdaq Stockholm. About us At a glance Rare diseases Therapeutic areas Haematology Immunology Specialty Care portfolio Investors Reports & presentations Share information Calendar Career Open positions Meet our employees Media Press releases Gallery Sobiplay Sitemap Cookie Policy Privacy Policy Terms of use Cookies Settings © Swedish Orphan Biovitrum AB (publ) Reg. no. 556038-9321 This website uses cookies By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Accept All Cookies Cookies Settings